The CRC Digest

Curated CRC research — accessible, accurate, actionable

Thursday, April 02, 2026

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ Endoscopist quality at both screening and surveillance colonoscopy affects cancer risk

  Higher adenoma detection rates and longer withdrawal times at both initial screening and follow-up surveillance colonoscopies were associated with lower risk of advanced colorectal neoplasia, suggesting that choosing an experienced endoscopist matters at every colonoscopy. (Clinical and Translational Gastroenterology)

• ▪ AI-assisted colonoscopy shows mixed results in real-world screening

  A randomized trial of 933 patients in private practices found that the EndoMind AI detection system did not significantly improve adenoma detection rates compared to traditional colonoscopy, adding to ongoing debate about AI's clinical value in routine screening. (NPJ Digital Medicine)

• ▸ Alternative administration routes for BRAF-targeted therapy in bowel obstruction

  Case report demonstrates that encorafenib (a BRAF V600E inhibitor) can be administered via gastric or rectal tube in patients with bowel obstruction who cannot swallow pills, potentially maintaining treatment continuity when oral intake is impossible. (The Oncologist)

• ♥ Bowel obstruction risk identified during immunotherapy for MSI-H colorectal cancer

  Multicenter study found that some MSI-H/dMMR colorectal cancer patients develop bowel obstruction during tumor regression on immunotherapy, with researchers developing a Bayesian model to assess individual risk based on clinical and molecular features. (Immunotargets and Therapy)

• ▪ Fecal hemoglobin testing improves survival in symptomatic patients

  Retrospective study shows that using fecal hemoglobin levels to prioritize which symptomatic patients get colonoscopy first was associated with improved colorectal cancer-specific survival, suggesting this approach helps identify high-risk patients more quickly. (British Journal of Cancer)

Today's research highlights the importance of screening quality and brings practical solutions for treatment challenges — progress happens one study at a time.